Double-Blind Study is best described as which of the following?

• A. Phase II Testing
• B. Double-Blind Study
• C. Crossover Study
• D. Phase IV Testing

Answer: (B)

Blinding design is the focus here. A double-blind study means that neither the participants nor the researchers who interact with them or assess outcomes know which treatment the participant is receiving. This masking helps prevent expectations from influencing behavior, reporting, or assessment, which could otherwise skew the results. It specifically aims to reduce bias in the measurement of outcomes.

This isn’t about the phase of drug development (Phase II or Phase IV), which describe when a trial occurs in the development process, nor is it defined by a crossover structure where participants receive multiple treatments in sequence. The defining feature is the masking of treatment identity to both sides, which is why this option best matches the description.